Press Releases

WuXi XDC (stock code: 2268.HK ), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) specializing in antibody drug bioconjugates (“ADCs”) and bioconjugates, has received multiple prestigious ESG (Environmental, Social, and Governance) awards from various industry organizations. These accolades underscore the company’s exceptional performance and management in environmental, social, and governance areas, while affirming its unwavering commitment to sustainable development.

Dr. Jimmy Li, CEO and Chairman of the ESG Committee at WuXi XDC, remarked, “We are deeply honored to be recognized by the industry, which reflects our steadfast commitment to advancing ESG initiatives. At WuXi XDC, we view ESG as an integral part of our corporate governance and development strategy. Looking ahead, we will continue to lead the bioconjugate industry by implementing sustainable development strategies, promoting ESG excellence, enhancing our management practices, creating long-term social value, and achieving even greater progress.”

• Recognized in the Competitiveness Series Rankings of Chinese Pharmaceutical Listed Companies

WuXi XDC was featured in the Competitiveness Series Rankings of Chinese Pharmaceutical Listed Companies published by Healthcare Executive magazine. For its exemplary transparency and performance in ESG evaluation, WuXi XDC received the titles of “Top 20 Pharmaceutical Listed Companies in ESG Competitiveness 2024” and “Responding to Climate Change – Top 10 Low Carbon Pioneers Among Chinese Pharmaceutical Listed Companies 2024.”

• Featured on KPMG China’s ESG 50 List

WuXi XDC was also included in the “2024 Technology-Enabled ESG List” by KPMG China’s ESG 50. This list celebrates enterprises that demonstrate exceptional achievements and innovation in ESG practices. It highlights organizations leveraging technological resources, influence, and expertise to advance sustainable development. WuXi XDC’s inclusion in the list underscores its leading position in ESG management and progress in achieving sustainability goals.

• “Best ESG Newcomer” at the 8th China Excellence IR Awards

WuXi XDC was honored with the “Best ESG Newcomer Award” at the 8th China Excellence IR Awards. This recognition reflects the capital market’s strong endorsement of WuXi XDC’s ESG governance and its long-term investment value. Co-organized by Roadshow China and IR Excellence, the China Excellence IR Awards are among the most influential accolades in investor relations within the country.

• Achieved an A Rating in the Wind ESG Rankings

WuXi XDC recently earned an A rating in the Wind ESG rankings, with overall and individual scores surpassing industry averages. This recognition highlights the company’s outstanding performance in corporate governance, human rights, labor practices, environmental protection, and community engagement. The Wind ESG rating is based on international standards and evaluation frameworks, assessing substantive ESG risks and sustainable operational capabilities of companies.

Previously, WuXi XDC was also ranked in the top 10% of companies globally and awarded a “Low Risk” rating in the 2024 ESG corporate risk assessment by Morningstar Sustainalytics , maintaining a leading position in the CRDMO field.

About WuXi XDC

WuXi XDC Cayman Inc.  (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.

WuXi XDC Contacts

ESG：ESG_WuXi_XDC@wuxibiologics.com

Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com